U
GNMK

UBS’s GenMark Diagnostics, Inc GNMK Stock Holding History

UBS’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$157K Sell
17,500
-5,045
-22% -$54.3K ﹤0.01% 5454
2014
Q2 		$305K Sell
22,545
-955
-4% -$9.96K ﹤0.01% 4726
2014
Q1 		$234K Sell
23,500
-51
-0.2% -$634 ﹤0.01% 5018
2013
Q4 		$313K Sell
23,551
-2,642
-10% -$32.1K ﹤0.01% 4810
2013
Q3 		$318K Sell
26,193
-4,707
-15% -$50.5K ﹤0.01% 4626
2013
Q2 		$320K Buy
+30,900
New +$426K ﹤0.01% 4573

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS's GNMK Position: Q3 2014 in Review

UBS reduced its GenMark Diagnostics, Inc (GNMK) stake by 22% in Q3 2014, selling an estimated $54.3K and leaving 17,500 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #5454.

UBS first reported a position in GNMK in Q2 2013 and has held it in 6 quarters since. The position peaked at $320K in Q2 2013. 82 funds tracked by Wall St. Rank hold GNMK as of Q3 2014.

  • UBS held 17,500 shares of GenMark Diagnostics, Inc worth $157K as of Q3 2014.
  • UBS sold 5,045 GenMark Diagnostics, Inc shares in Q3 2014, an estimated $54.3K.
  • GenMark Diagnostics, Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5454 holding.
  • UBS first reported a position in GenMark Diagnostics, Inc in Q2 2013 and has held it in 6 quarters since.
  • UBS's GenMark Diagnostics, Inc position peaked at $320K in Q2 2013.
  • 82 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.